This map is based on research-front data for the fourth bimonthly period of
2009, September 30, 2003-August 31, 2009 (sliding 6-year period). The map shows the major subject areas within fields linked together
in a network based on the same principles as our research-front maps showing
highly cited papers. To create a map of science, we start with all research
fronts in
Essential Science IndicatorsSM
from Thomson
Reuters, and compute the links between fronts based on how often they
are co-cited—that is, the frequency that current papers jointly cite two given
fronts. Successive applications of a clustering process then groups fronts into
larger aggregates. Each circle on the map represents a cluster or aggregate of
research fronts on a broad topic within that field. Annotations have been added
to this map which represent the main research themes. These appear as labels
attached to specific regions on the maps.
Additional information about Research Fronts.
Label: 12 CONTROLLED DETERMINISTIC SECURE QUANTUM COMMUNICATION USING FIVE-QUBIT ENTANGLED STATES; HIGH-SPEED LINEAR OPTICS QUANTUM COMPUTING USING ACTIVE FEED-FORWARD; CHARGE-BASED QUANTUM COMPUTING USING SINGLE DONORS Discipline: Level 2 Docs: 12 Tot. Cites: 31114; Uniq. Cites: 27706 Mean Year: 2005.80
Label: 205 ENGINEERING BONE-LIKE TISSUE IN-VITRO USING HUMAN BONE MARROW STEM CELLS; BONE TISSUE ENGINEERING USING HUMAN MESENCHYMAL STEM CELLS; IN-VITRO TISSUE-ENGINEERED BONE-LIKE STRUCTURES USING HUMAN MESENCHYMAL STEM CELLS Discipline: Level 2 Docs: 11 Tot. Cites: 18436; Uniq. Cites: 16275 Mean Year: 2005.20
Label: 147 HOSPITAL QUALITY ALLIANCE PROGRAM US HOSPITAL CARE; HEALTH CARE DISPARITIES QUALITY REPORTING-PAY-FOR-PERFORMANCE EFFECTS; HEALTH CARE QUALITY; ACCOUNTABLE CARE ORGANIZATION CREATION EXTENDED HOSPITAL MEDICAL STAFF; ADDRESS HEALTH CARE DISPARITIES Discipline: Level 2 Docs: 7 Tot. Cites: 6694; Uniq. Cites: 6403 Mean Year: 2006.10
Label: 40 ORAL DIRECT FACTOR XA INHIBITOR RIVAROXABAN (BAY 59-7939); ORAL DIRECT FACTOR XA INHIBITOR APIXABAN; ODIXA-DVT (ORAL DIRECT FACTOR XA INHIBITOR BAY 59-7939; THE BIRMINGHAM ATRIAL FIBRILLATION TREATMENT OF THE AGED STUDY Discipline: Level 2 Docs: 2 Tot. Cites: 4670; Uniq. Cites: 4530 Mean Year: 2005.50
Label: 258 PRINTED COVALENT GLYCAN ARRAY DIVERSE GLYCAN BINDING PROTEIN LIGAND PROFILING; CHEMICAL PROTEIN MODIFICATION; SITE-SELECTIVE PROTEIN MODIFICATION; MATRIX-ASSISTED LASER DESORPTION/IONIZATION MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY Discipline: Level 2 Docs: 2 Tot. Cites: 1806; Uniq. Cites: 1785 Mean Year: 2006.90
Label: 309 ALTERNATIVE PRE-MESSENGER RNA SPLICING MECHANISMS; ALTERNATIVE SPLICING ISOFORMS USING GENERATIVE MODEL; UNBALANCED ALTERNATIVE SPLICING CANCER SIGNIFICANCE; UNDERSTANDING ALTERNATIVE SPLICING; ALTERNATIVE PRE-MRNA SPLICING Discipline: Level 2 Docs: 2 Tot. Cites: 1551; Uniq. Cites: 1523 Mean Year: 2006.20
Label: 397 GENERAL HEALTH STATUS; SELF-REPORTED HEALTH STATUS; LIFE COURSE SOCIOECONOMIC FACTORS; LIFE COURSE APPROACH; LIFE COURSE PROCESSES Discipline: Level 2 Docs: 2 Tot. Cites: 1293; Uniq. Cites: 1280 Mean Year: 2005.40
Label: 245 HEALTH INFORMATION NATIONAL TRENDS SURVEY (HINTS); OFFLINE HEALTH INFORMATION SEEKERS; OBTAIN HEALTH INFORMATION; MEN'S HEALTH BEHAVIORS; PERCEIVED NORMATIVE HEALTH BEHAVIORS Discipline: Level 2 Docs: 2 Tot. Cites: 793; Uniq. Cites: 785 Mean Year: 2005.30
Label: 448 EUROPEAN LAND USE FUTURE DYNAMICS ANALYSIS; FLOODPLAIN LAND USE; ASSESSING RIVER BIOTIC CONDITION; LAND CHANGE; ECOLOGICAL CONDITION Discipline: Level 2 Docs: 2 Tot. Cites: 595; Uniq. Cites: 581 Mean Year: 2006.60
Label: 150 MEDICARE PART D PRESCRIPTION BENEFIT; MEDICARE PRESCRIPTION DRUG BENEFIT PROGRESS REPORT; BREAST CANCER PATIENT TREATMENT INFORMED DECISION; PATIENT DECISION AIDS QUALITY CRITERIA FRAMEWORK DEVELOPMENT ONLINE INTERNATIONAL DELPHI CONSENSUS PROCESS Discipline: Level 2 Docs: 2 Tot. Cites: 396; Uniq. Cites: 380 Mean Year: 2006.60